patent for semaglutide Last week's expiry of the semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions The patent for semaglutide the

By activating GLP-1 receptors, these treatments may help reduce hunger, increase fullness after meals, and support lower calorie intake

Figure 6 Prevalence of mycotoxins in different geographic regions As discussed in the previous sections, the worldwide occurrence of AFs depends on several factors such as climate, the availability of standard crop/food storage facilities, the awareness of local farmers, food processing methods, post-harvest contaminations, and temperature and moisture of post-harvest storage sites

Most possible side effects are not serious

A one-size-fits-all cutoff can miss the patients at the highest metabolic risk